LA
VRTX icon

Lifeworks Advisors’s Vertex Pharmaceuticals VRTX Stock Holding History

Lifeworks Advisors’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.61M Buy
3,242
+220
+7% +$97.5K 0.17% 109
2026
Q1 		$1.35M Buy
3,022
+99
+3% +$46.2K 0.17% 111
2025
Q4 		$1.33M Buy
2,923
+9
+0.3% +$3.88K 0.17% 121
2025
Q3 		$1.14M Buy
2,914
+260
+10% +$109K 0.15% 126
2025
Q2 		$1.18M Sell
2,654
-501
-16% -$231K 0.18% 113
2025
Q1 		$1.53M Sell
3,155
-529
-14% -$247K 0.25% 93
2024
Q4 		$1.48M Sell
3,684
-8,169
-69% -$3.79M 0.27% 98
2024
Q3 		$5.51M Sell
11,853
-560
-5% -$269K 1.08% 26
2024
Q2 		$5.82M Buy
12,413
+1,816
+17% +$788K 1.62% 16
2024
Q1 		$4.43M Buy
10,597
+1,496
+16% +$632K 1.24% 25
2023
Q4 		$3.7M Buy
9,101
+738
+9% +$273K 1.28% 23
2023
Q3 		$2.91M Buy
+8,363
New +$2.92M 1.13% 26

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Lifeworks Advisors's VRTX Position: Q2 2026 in Review

Lifeworks Advisors increased its Vertex Pharmaceuticals (VRTX) stake by 7.3% in Q2 2026, buying an estimated $97.5K and bringing the position to 3,242 shares worth $1.61M. The position accounts for 0.17% of the portfolio, ranked #109.

Lifeworks Advisors first reported a position in VRTX in Q3 2023 and has held it in 12 quarters since. The position peaked at $5.82M in Q2 2024. 1,758 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

  • Lifeworks Advisors held 3,242 shares of Vertex Pharmaceuticals worth $1.61M as of Q2 2026.
  • Lifeworks Advisors bought 220 Vertex Pharmaceuticals shares in Q2 2026, an estimated $97.5K.
  • Vertex Pharmaceuticals made up 0.17% of Lifeworks Advisors's portfolio in Q2 2026, its #109 holding.
  • Lifeworks Advisors first reported a position in Vertex Pharmaceuticals in Q3 2023 and has held it in 12 quarters since.
  • Lifeworks Advisors's Vertex Pharmaceuticals position peaked at $5.82M in Q2 2024.
  • 1,758 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Lifeworks Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.